232 related articles for article (PubMed ID: 34967815)
1. Triple negative breast cancer: any closer to cracking the code?
Peddi PF
Curr Opin Obstet Gynecol; 2022 Feb; 34(1):52-55. PubMed ID: 34967815
[TBL] [Abstract][Full Text] [Related]
2. [Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Dalenc F; Sarradin V; Nicolaï V; Franchet C; Ung M
Bull Cancer; 2021 Jan; 108(1):67-79. PubMed ID: 33422340
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates.
Nagayama A; Vidula N; Bardia A
Oncology (Williston Park); 2021 May; 35(5):249-254. PubMed ID: 33983696
[TBL] [Abstract][Full Text] [Related]
4. Molecular Classification of Triple Negative Breast Cancer and the Emergence of Targeted Therapies.
Sakach E; O'Regan R; Meisel J; Li X
Clin Breast Cancer; 2021 Dec; 21(6):509-520. PubMed ID: 34629314
[TBL] [Abstract][Full Text] [Related]
5. Novel Neoadjuvant Treatment Strategies for Triple-Negative Breast Cancer.
Davis AA; Gradishar WJ
Oncology (Williston Park); 2020 May; 34(5):176-182. PubMed ID: 32644178
[TBL] [Abstract][Full Text] [Related]
6. New strategies for the management of triple-negative breast cancer.
Riaz F
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):40-44. PubMed ID: 38170551
[TBL] [Abstract][Full Text] [Related]
7. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
8. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Okuma HS; Yonemori K
Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689
[TBL] [Abstract][Full Text] [Related]
9. Targeted Treatment of Triple-Negative Breast Cancer.
Young JA; Tan AR
Cancer J; 2021 Jan-Feb 01; 27(1):50-58. PubMed ID: 33475293
[TBL] [Abstract][Full Text] [Related]
10. Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy.
Prasanna T; Wu F; Khanna KK; Yip D; Malik L; Dahlstrom JE; Rao S
Cancer Sci; 2018 Nov; 109(11):3383-3392. PubMed ID: 30230653
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates in triple negative breast cancer.
Tray N; Adams S; Esteva FJ
Future Oncol; 2018 Oct; 14(25):2651-2661. PubMed ID: 30175620
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
[TBL] [Abstract][Full Text] [Related]
14. New Therapeutic Strategies for Triple-Negative Breast Cancer.
Székely B; Silber AL; Pusztai L
Oncology (Williston Park); 2017 Feb; 31(2):130-7. PubMed ID: 28205193
[TBL] [Abstract][Full Text] [Related]
15. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
Dawood S; Konstantinova M; Perazzo F; Kim SB; Villarreal-Garza C; Franco SX; Simon SD; El-Nahas T
Chin Clin Oncol; 2020 Oct; 9(5):61. PubMed ID: 32819114
[TBL] [Abstract][Full Text] [Related]
17. PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
Geenen JJJ; Linn SC; Beijnen JH; Schellens JHM
Clin Pharmacokinet; 2018 Apr; 57(4):427-437. PubMed ID: 29063517
[TBL] [Abstract][Full Text] [Related]
18. Advances in Targeted Therapies for Triple-Negative Breast Cancer.
McCann KE; Hurvitz SA; McAndrew N
Drugs; 2019 Jul; 79(11):1217-1230. PubMed ID: 31254268
[TBL] [Abstract][Full Text] [Related]
19. Triple-negative breast cancer: recent treatment advances.
Bergin ART; Loi S
F1000Res; 2019; 8():. PubMed ID: 31448088
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in targeted strategies for triple-negative breast cancer.
Zhu S; Wu Y; Song B; Yi M; Yan Y; Mei Q; Wu K
J Hematol Oncol; 2023 Aug; 16(1):100. PubMed ID: 37641116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
